Of note, KCa3.1 blockade reduced several aspects of TGFβ1-dependent EMT, suggesting that KCa3.1 blockers may reduce airway wall fibrosis in asthma and COPD. This evidence concerns the gene TGFB1 and chronic obstructive pulmonary disease.